Yarrow Bioscience, Inc. 是一家临床阶段的生物技术公司,致力于开发针对自身免疫性甲状腺疾病的变革性疗法。公司总部位于纽约州纽约市。
财务指标
营业收入
2026-09-30
--
2026-06-30
$9.7万
2026-03-31
$8.6万
2025-12-31
$13万
营业支出
2026-09-30
$1074.3万
2026-06-30
$319.3万
2026-03-31
$389.6万
2025-12-31
$534.9万
净利润
2026-09-30
-$972.4万
2026-06-30
-$300.7万
2026-03-31
-$358.5万
2025-12-31
-$483.7万
净利润率
2026-09-30
--
2026-06-30
-3.1K%
2026-03-31
-4.16K%
2025-12-31
-3.72K%
每股收益
2026-09-30
$-0.43
2026-06-30
$-2.14
2026-03-31
$-4.19
2025-12-31
--
息税折旧摊销前利润
2026-09-30
-$972.4万
2026-06-30
-$289.3万
2026-03-31
-$357.9万
2025-12-31
-$495.1万
有效税率
2026-09-30
--
2026-06-30
--
2026-03-31
--
2025-12-31
-0.08%
项目
2026-09-30
2026-06-30
2026-03-31
2025-12-31
营业收入
--
$9.7万
$8.6万
$13万
营业支出
$1074.3万
$319.3万
$389.6万
$534.9万
净利润
-$972.4万
-$300.7万
-$358.5万
-$483.7万
净利润率
--
-3.1K%
-4.16K%
-3.72K%
每股收益
$-0.43
$-2.14
$-4.19
--
息税折旧摊销前利润
-$972.4万
-$289.3万
-$357.9万
-$495.1万
有效税率
--
--
--
-0.08%
常见问题
YARW represents a publicly traded equity security available on U.S. markets. The ticker identifies the specific company and its common shares. For accurate details about the underlying business, investors should review the latest YARW company profile and disclosures available on this page and through regulatory filings. Shares can be bought or sold through brokerage accounts, and the stock may be referenced in market data platforms and financial news sources.
The industry classification for YARW is listed in the stock's profile data on this page. Industry context helps investors compare YARW against peers and understand sector-specific risks and opportunities. Because classifications can vary by data provider, reviewing the company's official filings and sector information is useful. The industry also influences how macroeconomic trends and regulatory changes may affect YARW's operations and stock performance over time.
Recent performance for YARW is displayed in the price chart and performance data on this page. Short-term price movements can be driven by company news, broader market trends, and sector developments. For the most current figures, including daily and year-to-date changes, refer to the live data provided here. Historical return comparisons should be made over consistent time frames.
The price-to-earnings ratio for YARW depends on the current share price and the company's trailing or forward earnings, which may not be available for all companies. Check this page for the latest displayed P/E and related valuation metrics. If the figure is not shown, it may be because YARW has no meaningful earnings or the data is not provided. Compare the P/E to industry peers and the company's own history for context.
Earnings reports, including revenue, net income, and earnings per share, are typically available through the company's investor relations site and SEC filings such as 10-Q and 10-K reports. This page may also summarize recent quarterly results and earnings dates for YARW. Reviewing multiple periods helps investors assess trends. Earnings releases often include management commentary and guidance that can influence how the stock reacts.
Risks for YARW include company-specific factors such as competition, execution, and financial leverage, as well as broader market and economic risks. Sector conditions, interest rates, and regulatory changes can also affect performance. Reviewing YARW's risk factors in its latest annual report or 10-K provides detailed disclosure. Concentration, liquidity, and valuation risks may apply, and the stock's price can be volatile.